Oncolytic virus Ad-TD-nsIL-12 inhibits glioma growth and reprograms the tumor immune microenvironment.

导出 LinkOut

翻译打印收藏纠错

作者： Shenglun,Li ^[1] ; Yuduo,Guo ^[2] ; Weihai,Ning ^[1] ; Yujia,Chen ^[1] ; Jiacheng,Xu ^[1] ; Chao,Zhao ^[1] ; Jun,Wang ^[1] ; Yanming,Qu ^[1] ; Mingshan,Zhang ^[1] ; Pengju,Wang ^[3] ; Yaohe,Wang ^[4] ; Shengdian,Wang ^[5] ; Hongwei,Zhang ^[6]

作者单位： Department of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, China. ^[1] Department of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, China; CAS Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China. ^[2] Sino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, State Key Laboratory of Esophageal Cancer Prevention & Treatment, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, China. ^[3] Centre for Cancer Biomarkers & Biotherapeutics, Barts Cancer Institute - a Cancer Research, UK Centre of Excellence, Queen Mary University of London John Vane Science Centre, London EC1M 6BQ, United Kingdom. ^[4] CAS Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China. Electronic address: sdwang@ibp.ac.cn. ^[5] Department of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, China. Electronic address: zhanghongwei@ccmu.edu.cn. ^[6]

关键词 Glioma IL-12 Oncolytic virus T cell Tumor immune microenvironment